Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 12:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 7,721 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 2 Clear all
Completed Phase 2 Interventional Results available

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

NCT02260193
View directory record Official record
Conditions
Anemia, End Stage Renal Disease
Interventions
AKB-6548
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
El Granada, California • Long Beach, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 26, 2026, 12:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

NCT02918006
View directory record Official record
Conditions
Influenza
Interventions
VXA-A1.1, Fluzone®, Placebo Tablets, Saline Solution for Placebo IM Injection
Biological · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Costa Mesa, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 26, 2026, 12:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized Controlled Trial of the Bruthas Project

NCT01270230
View directory record Official record
Conditions
HIV Infection
Interventions
Bruthas Project, Standard HIV Testing and Counseling
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
396 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 26, 2026, 12:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

Accelerated rTMS vs. Sham for Stroke Apathy

NCT07113067
View directory record Official record
Conditions
Apathy, Stroke, Stroke Sequelae, Stroke/Brain Attack, Stroke/ Cerebrovascular Accident (Ischemic or Hemorrhagic), Motivation, Abulia
Interventions
MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active), MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham), Brainsight Neuronavigation System
Device · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 26, 2026, 12:29 AM EDT
Terminated Phase 1 Interventional Results available

A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

NCT02309892
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
L-DOS47
Drug
Lead sponsor
Helix BioPharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 26, 2026, 12:29 AM EDT
Completed Phase 1 Interventional Results available

Epigenetic Reprogramming in Relapse/Refractory AML

NCT03263936
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Decitabine, Vorinostat, Filgrastim (G-CSF), Fludarabine, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 25 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
28
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 26, 2026, 12:29 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants

NCT07242781
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986365, Itraconazole, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 26, 2026, 12:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Health Improvement Program: Effects of a Workplace Sugary Beverages Sales Ban and Motivational Counseling

NCT05972109
View directory record Official record
Conditions
Obesity, Abdominal, Insulin Sensitivity
Interventions
Workplace SSB sales ban, Brief Intervention
Other · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 26, 2026, 12:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Novel Determinants and Measures of Smokeless Tobacco Use: Study 2

NCT01067599
View directory record Official record
Conditions
Tobacco Use Disorder, Nicotine Dependence
Interventions
Low nicotine, Medium nicotine, High nicotine
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Minneapolis, Minnesota • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 26, 2026, 12:29 AM EDT
Terminated Phase 1 Interventional

An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)

NCT01742793
View directory record Official record
Conditions
Hodgkin's Lymphoma, Mature T-cell Lymphoma, Multiple Myeloma
Interventions
lenalidomide (Revlimid) and romidepsin (Istodax)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 26, 2026, 12:29 AM EDT
Recruiting Phase 1 Interventional

Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

NCT07220993
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
Interventions
CD7.CAR/28zeta T Cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2043
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 26, 2026, 12:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Using MOVE! With Seriously Mentally Ill Veterans

NCT00323193
View directory record Official record
Conditions
Mental Illness, Obesity
Interventions
MOVE!
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 26, 2026, 12:29 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Ferric Citrate to Improve Inflammation and Lipid Levels

NCT02661295
View directory record Official record
Conditions
End Stage Renal Disease, Hyperphosphatemia, Chronic Inflammation
Interventions
Ferric Citrate
Drug
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 26, 2026, 12:29 AM EDT
Not listed Not applicable Interventional

Intraoperative Monitoring of Femoral Head Perfusion

NCT04110639
View directory record Official record
Conditions
Femoral Neck Fractures
Interventions
Intracranial pressure (ICP) monitor, Standard of Care
Device · Other
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
1 Year to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 26, 2026, 12:29 AM EDT
Completed Phase 2 Interventional

Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)

NCT07016412
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg, Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
57
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 26, 2026, 12:29 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Optimizing an Evidence-Based, Disseminable, Free Internet-Based Parenting Program

NCT05689736
View directory record Official record
Conditions
Parenting Practices
Interventions
Motivational Enhancement, Simplification, Gamification, Low Engagement Nudges, Essentials for Parenting Toddlers and Pre-schoolers (EFP)
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 99 Years
Enrollment
859 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 26, 2026, 12:29 AM EDT
Not listed Not applicable Interventional

Cost Effectiveness and Clinical Utility of Cell Saver Use for Two to Three Level Lumbar Fusions

NCT01453309
View directory record Official record
Conditions
Low Back Pain Unresponsive to Non-surgical Care
Interventions
Cell Saver, No Cell Saver
Procedure
Lead sponsor
Norton Leatherman Spine Center
Other
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 26, 2026, 12:29 AM EDT
Completed Phase 3 Interventional Results available

Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)

NCT00406393
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
Interventions
Tacrolimus, Methotrexate, Sirolimus
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 60 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
23
States / cities
Duarte, California • La Jolla, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 26, 2026, 12:29 AM EDT
Completed Phase 1 Interventional

A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors

NCT00784914
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions
temsirolimus, pharmacological study, cytokine levels
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 26, 2026, 12:29 AM EDT
Terminated Phase 3 Interventional Results available

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

NCT03626545
View directory record Official record
Conditions
Non-Small-Cell Lung
Interventions
Canakinumab, Docetaxel, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 26, 2026, 12:29 AM EDT
Recruiting Phase 1 Interventional

Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

NCT07290244
View directory record Official record
Conditions
Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Interventions
ER-100 epigenetic therapy
Genetic
Lead sponsor
Life Biosciences Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Glendale, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 26, 2026, 12:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

NCT03919409
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TS-161, TS-161 Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 26, 2026, 12:29 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma

NCT00587132
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Synthetic Human Secretin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 26, 2026, 12:29 AM EDT
Completed Phase 1 Interventional

Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

NCT02546531
View directory record Official record
Conditions
Advanced Solid Tumors, Solid Tumors, Pancreatic Cancer
Interventions
Defactinib, Pembrolizumab, Gemcitabine
Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 26, 2026, 12:29 AM EDT